Trials / Completed
CompletedNCT01063621
Extended Long-Term Safety Study of KW-6500
Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a extended long-term safety study in Parkinson's disease patients who have motor response complications on levodopa therapy and completed 12 weeks administrations of KW-6500 in 6500-004 study. The safety and efficacy of long-term subcutaneous self-injections of KW-6500 are evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-6500 | Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-08-01
- Completion
- 2012-03-01
- First posted
- 2010-02-05
- Last updated
- 2017-03-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01063621. Inclusion in this directory is not an endorsement.